Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
A more selective growth-hormone secretagogue, usually discussed alongside CJC-1295 — never FDA-approved as a standalone drug.
Ipamorelin is often sold as the "gentler" growth-hormone peptide because of its receptor selectivity. That's a real pharmacological distinction — it doesn't mean it's an approved or fully evidence-backed drug on its own.
A note on regulatory status (as of July 2026): Ipamorelin was placed in FDA Category 2 in late 2023, then returned to Category 1 in the April 2026 reclassification — meaning it can currently be legally compounded with a prescription, but this is not FDA drug approval, and the FDA has separately flagged limited clinical data and immunogenicity/impurity concerns for this compound. Confirm current status before use.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor — similar in concept to older secretagogues like GHRP-6, but designed to be more selective, with less effect on cortisol and prolactin than earlier compounds in this class. It has never completed the trial process for FDA approval as a standalone drug.
By activating the ghrelin receptor in the pituitary and hypothalamus, ipamorelin triggers a pulse of growth hormone release. It's frequently paired with a GHRH analog like CJC-1295, which works on a different receptor — the combination is intended to amplify the GH pulse more than either compound alone.
Selectivity for the ghrelin receptor (versus older, less selective secretagogues) is reasonably well documented in pharmacology research. Evidence for the clinical outcomes it's marketed for — body composition, recovery, sleep quality — in adults using it off-label is comparatively limited and largely observational or extrapolated from the growth-hormone-axis literature more broadly, not large trials of ipamorelin itself.
Reported issues are typically mild — injection-site reactions, transient flushing, headache — and generally milder than older, less selective secretagogues. The FDA's own review flagged limited long-term clinical data as a specific concern, which is the honest framing: milder in the mechanisms that are understood, less established in the outcomes that matter to most users.
Ipamorelin's receptor selectivity is a real, meaningful design improvement over older secretagogues — but "more selective" is a mechanism claim, not an outcomes guarantee. It belongs in a provider-managed protocol with lab monitoring, not a self-directed stack.
Regulatory status as of 2026-07-20.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense ipamorelin or any medication.